Compositions and methods for the treatment of carboxyhemoglobinemia
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsMark Thomas Gladwin, Jesus Tejero Bravo
Life of this patent
Estimating the term…
Abstract
Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
Claims16
A method of treating carboxyhemoglobinemia in a subject, comprising:
- selecting a subject with carboxyhemoglobinemia;
- and
- administering to the subject a therapeutically effective amount of a human recombinant neuroglobin, comprising:
- a H64Q, H64A, or H64W mutation, and
- a C46G mutation, a C55S mutation, a C120S mutation, or any combination thereof.
A method of treating carboxyhemoglobinemia in a subject, comprising:
- selecting a subject with carboxyhemoglobinemia;
- and
- administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:
- a human recombinant neuroglobin comprising:
- a H64Q, H64A or H64W mutation;
- and
- a C46G mutation, a C55S mutation, a C120S mutation, or any combination thereof;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.